[HTML][HTML] Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
JE Ebinger, J Fert-Bober, I Printsev, M Wu, N Sun… - Nature medicine, 2021 - nature.com
JE Ebinger, J Fert-Bober, I Printsev, M Wu, N Sun, JC Prostko, EC Frias, JL Stewart…
Nature medicine, 2021•nature.comIn a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition
responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection
(n= 35) were similar to those seen after two doses of vaccine in individuals without prior
infection (n= 228). Post-vaccine symptoms were more prominent for those with prior infection
after the first dose, but symptomology was similar between groups after the second dose.
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition
responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection
(n= 35) were similar to those seen after two doses of vaccine in individuals without prior
infection (n= 228). Post-vaccine symptoms were more prominent for those with prior infection
after the first dose, but symptomology was similar between groups after the second dose.
Abstract
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
nature.com